---
layout: post
title: "西南证券维持长春高新买入评级：百克生物拖累业绩 长效生长激素放量值得期待"
date: 2022-03-20 17:16:43 +0800
categories: meirijingjixinwen
tags: 每日经济新闻新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.000661" data-code="000661|0|2" data-code2="000661|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.000661&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 000661_0" data-code="K 000661|0|2" data-code2="K 000661|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p><span id="stock_1.600369"><a href="http://quote.eastmoney.com/unify/r/1.600369" class="keytip" data-code="1,600369">西南证券</a></span><span id="quote_1.600369"></span>03月20日发布<span id="Info.3319"><a href="http://data.eastmoney.com/report/" class="infokey">研报</a></span>称，维持<span id="stock_0.000661"><a href="http://quote.eastmoney.com/unify/r/0.000661" class="keytip" data-code="0,000661">长春高新</a></span><span id="quote_0.000661"></span>(000661.SZ，最新价：172.6元)买入评级。评级理由主要包括：1)金赛药业<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>快速增长，生长激素持续放量；2)<span id="stock_1.688276"><a href="http://quote.eastmoney.com/unify/r/1.688276" class="keytip" data-code="1,688276">百克生物</a></span><span id="quote_1.688276"></span>拖累业绩，带状疱疹疫苗值得期待；3)地产和中成药业务平稳增长，有望继续贡献稳定现金流。风险提示：生长激素放量不及预期的风险；在研产品进度不及预期的风险。<br /></p>
 <p>AI点评：<span web="1" href="http://quote.eastmoney.com/unify/r/0.000661" class="em_stock_key_common" data-code="0,000661">长春高新</span>近一个月获得7份<span id="Info.3306"><a href="http://data.eastmoney.com/other/qsjy.html" class="infokey">券商</a></span>研报关注，买入7家，平均目标价为244.35元，与最新价172.6元相比，高71.75元，目标均价涨幅41.57%。</p><p class="em_media">（文章来源：每日经济新闻）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202203202316299891>

[返回每日经济新闻新闻](//finews.withounder.com/category/meirijingjixinwen.html)｜[返回首页](//finews.withounder.com/)